tirzepatide discovery is a first-in-class dual agonist targeting both GIP and GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management. By acting on multiple metabolic pathways, tirzepatide: Enhances Tirzepatide - 2023788-19-2 - Discovery

Peptide begins engaging cellular pathways

FDA Designations for ARD-101 The FDA approves ARD-101 Orphan Drug designation and Rare Pediatric Disease designation for its potential to treat Prader-Willi Syndrome

Weve heard of young people even needing amputations or skin grafting as a result of this. Jones said some people were developing severe infections at the injection site, which he said was caused by bacterial contamination of the peptides during the manufacturing process

This is not an error

The World Health Organization (WHO) has issued a formal safety alert confirming that semaglutide medications, including Ozempic , Wegovy , and Rybelsus are associated with a very rare but serious risk of permanent vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)